OS Therapies Inc Dossier
Qualitative Analysis
Business overview
OS Therapies Inc. (NYSE American: OSTX) is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's primary mission is to address the significant unmet medical need for new treatments in cancers of the bone in children and young adults. Its pipeline is anchored by two core drug technologies: OST-HER2, an off-the-shelf Listeria monocytogenes-based immunotherapy designed to target HER2-expressing cancer cells, and OST-tADC, a tunable antibody-drug conjugate platform currently in preclinical development.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Securing regulatory approvals for lead candidate OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma across the US, UK, Europe, and Australia. This includes navigating the EMA's rolling review of the Conditional Marketing Authorization (CMA) dossier and aligning with global agencies on 3-year overall survival as the primary endpoint.
Expected impact: Potential to achieve the first approved therapy for osteosarcoma in over four decades and secure a highly valuable Priority Review Voucher (PRV).
Advancing the next-generation tunable Antibody-Drug Conjugate (tADC) platform, featuring proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technologies. The company is concluding preclinical and toxicology trials for lead candidate OST-tADC-A (Exatecan-silanol-FRa) to prepare for an IND filing.
Expected impact: Establishes a highly differentiated ADC platform to address large solid tumor markets and stimulate out-licensing opportunities.
Spinning off the veterinary subsidiary, OS Animal Health, Inc. (OSAH), into an independent public entity to advance OST-HER2 for canine osteosarcoma.
Expected impact: Allows the veterinary business to operate independently with dedicated funding, while commercializing canine osteosarcoma treatments and generating non-dilutive value.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Consolidated full global intellectual property ownership of the Listeria monocytogenes immunotherapy platform supporting lead asset OST-HER2. The transaction eliminated $20 million in potential development and commercial milestone payments and reduced net royalties to 1.5%. It also added three clinical-stage assets (OST-AXAL, OST-503, OST-504) and eight preclinical programs targeting over 30 solid tumor indications.
Financial impact: Eliminated substantial future milestone payment liabilities and reduced royalty burdens, while temporarily increasing R&D expenses to support the expanded pipeline.
Strategic Partnerships
EVERSANA was selected to lead the US commercialization of OST-HER2 for pediatric osteosarcoma. This partnership provides OS Therapies with end-to-end commercial infrastructure, including market access, medical affairs, patient services, and field deployment, without requiring the company to spend significant capital building its own commercial team.
Terms: Terms include utilizing EVERSANA's integrated commercialization model to minimize upfront capital expenditure for OS Therapies.